Advertisement

Endocrine

, Volume 52, Issue 2, pp 222–225 | Cite as

The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis

  • Samuel D. VasikaranEmail author
  • S. A. Paul Chubb
Viewpoint

Abstract

The purpose of the present study was to examine of the current role of bone turnover markers (BTMs) in the management of osteoporosis. Perusal of the literature examines the available evidence for the utility of BTMs for decision to treat and for the monitoring of treatment for osteoporosis. There is no evidence for the use of BTMs for fracture risk calculation, decision to treat or for treatment selection. A very abnormal BTM value may be a clue to the presence of bone pathology other than uncomplicated osteoporosis. Whilst changes to BTMs following various osteoporosis treatments are well defined, their utility in monitoring individual patients has been less well established. Some fracture outcome-based data exist for the use of u-NTX target of <21 nmol BCE/mmol for antiresorptive therapy; the equivalent s-CTX level is ~250 ng/L. Suboptimal BTM response to treatment may indicate non-compliance or the presence of secondary causes of osteoporosis which may need addressing. Studies are needed to establish treatment targets based on fracture outcomes for commonly used BTMs for each established osteoporosis therapy.

Keywords

Bone remodelling Bone turnover marker Fracture Osteoporosis 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    P.D. Delmas, R. Eastell, P. Garnero, M.J. Seibel, J. Stepan, The use of biochemical markers of bone turnover in osteoporosis. Osteoporos. Int. 11, 2–17 (2000)CrossRefGoogle Scholar
  2. 2.
    T. Cundy, I.R. Reid, Paget’s disease of bone. Clin. Biochem. 45(1–2), 43–48 (2012)CrossRefPubMedGoogle Scholar
  3. 3.
    S. Vasikaran, R. Eastell, O. Bruyère, A.J. Foldes, P. Garnero, A. Griesmacher, M. McClung, H.A. Morris, S. Silverman, T. Trenti, D.A. Wahl, C. Cooper, J.A. Kanis, IOF-IFCC Bone Marker Standards Working Group, Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos. Int. 22, 391–420 (2011)CrossRefPubMedGoogle Scholar
  4. 4.
    D. Bauer, J. Krege, N. Lane, E. Leary, C. Libanati, P. Miller, G. Myers, S. Silverman, H.W. Vesper, D. Lee, M. Payette, S. Randall, National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos. Int. 23, 2425–2433 (2012)CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    P. Garnero, E. Sornay-Rendu, B. Claustra, P.D. Delmas, Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J. Bone. Miner. Res. 15(8), 1526–1536 (2000)CrossRefPubMedGoogle Scholar
  6. 6.
    P. Garnero, E. Hausherr, M.C. Chapuy, C. Marcelli, H. Grandjean, C. Muller, C. Cormier, G. Bréart, P.J. Meunier, P.D. Delmas, Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J. Bone Miner. Res. 11(10), 1531–1538 (1996)CrossRefPubMedGoogle Scholar
  7. 7.
    H. Johansson, A. Odén, J.A. Kanis, E.V. McCloskey, H.A. Morris, C. Cooper, S. Vasikaran, IFCC-IOF Joint Working Group on Standardisation of Biochemical Markers of Bone Turnover, A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif. Tissue Int. 94(5), 560–567 (2014)CrossRefPubMedGoogle Scholar
  8. 8.
    J.A. Kanis, O. Johnell, A. Oden, H. Johansson, E. McCloskey, FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 19, 385–397 (2008)CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    I. Baxter, A. Rogers, R. Eastell, N. Peel, Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice. Osteoporos. Int. 24(3), 941–947 (2013)CrossRefPubMedGoogle Scholar
  10. 10.
    D.C. Bauer, P. Garnero, M.C. Hochberg, A. Santora, P. Delmas, S.K. Ewing, D.M. Black, Fracture Intervention Research Group, Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J. Bone Miner. Res. 21(2), 292–299 (2006)CrossRefPubMedGoogle Scholar
  11. 11.
    P.D. Delmas, A.A. Licata, J.Y. Reginster, G.G. Crans, P. Chen, D.A. Misurski, R.B. Wagman, B.H. Mitlak, Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 39(2), 237–243 (2006)CrossRefPubMedGoogle Scholar
  12. 12.
    J.A. Clowes, N.F. Peel, R. Eastell, The impact of monitoring on adherence and persistence with antiresorptive treatment for Osteoporos Int postmenopausal osteoporosis: a randomized controlled trial. J. Clin. Endocrinol. Metab. 89, 1117–1123 (2004)CrossRefPubMedGoogle Scholar
  13. 13.
    P.D. Delmas, B. Vrijens, R. Eastell, C. Roux, H.A. Pols, J.D. Ringe, A. Grauer, D. Cahall, N.B. Watts, Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators, Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 92, 1296–1304 (2007)CrossRefPubMedGoogle Scholar
  14. 14.
    R. Eastell, I. Barton, R.A. Hannon, A. Chines, P. Garnero, P.D. Delmas, Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J. Bone Miner. Res. 18, 1051–1056 (2003)CrossRefPubMedGoogle Scholar
  15. 15.
    D.C. Bauer, D.M. Black, P. Garnero, M. Hochberg, S. Ott, J. Orloff, D.E. Thompson, S.K. Ewing, P.D. Delmas, Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J. Bone Miner. Res. 19, 1250–1258 (2004)CrossRefPubMedGoogle Scholar
  16. 16.
    P.D. Delmas, F. Munoz, D.M. Black, F. Cosman, S. Boonen, N.B. Watts, D. Kendler, E.F. Eriksen, P.G. Mesenbrink, R. Eastell, The HORIZON-PFT Research Group, Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J. Bone Miner. Res. 24, 1544–1551 (2009)CrossRefPubMedGoogle Scholar
  17. 17.
    P. Chen, J.H. Satterwhite, A.A. Licata, E.M. Lewiecki, A.A. Sipos, D.M. Misurski, R.B. Wagman, Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J. Bone Miner. Res. 20, 962–970 (2005)CrossRefPubMedGoogle Scholar
  18. 18.
    E. Fink, C. Cormier, P. Steinmetz, C. Kindermans, Y. Le Bouc, J.C. Souberbielle, Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos. Int. 1, 295–303 (2000)CrossRefGoogle Scholar
  19. 19.
    P. Bergmann, J.J. Body, S. Boonen, Y. Boutsen, J.P. Devogelaer, S. Goemaere, J.M. Kaufman, J.Y. Reginster, V. Gangji, Members of the Advisory Board on Bone Markers, Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int. J. Clin. Pract. 63, 19–26 (2009)CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    R. Eastell, P. Garnero, C. Audebert, D. Cahall, Reference intervals of bone turnover markers in healthy premenopausal women: results from a cross-sectional European study. Bone 50(5), 1141–1147 (2012)CrossRefPubMedGoogle Scholar
  21. 21.
    S.A. Chubb, C.D. Mandelt, S.D. Vasikaran, Comparison of results from commercial assays for plasma CTX: the need for harmonization. Clin. Biochem. 48, 519–524 (2015)CrossRefPubMedGoogle Scholar
  22. 22.
    D.A. Eekman, I.E. Bultink, A.C. Heijboer, B.A. Dijkmans, W.F. Lems, Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice. BMC Musculoskelet. Disord. 12, 167 (2001)CrossRefGoogle Scholar
  23. 23.
    R. Eastell, B. Vrijens, D.L. Cahall, J.D. Ringe, P. Garnero, N.B. Watts, Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence. J. Bone Miner. Res. 26(7), 1662–1669 (2011)CrossRefPubMedGoogle Scholar
  24. 24.
    S.A. Chubb, C. Mandelt, S. Vasikaran, Comparison of clinical cut-points and treatment targets for urine NTX and plasma βCTX-I in osteoporosis. Clin. Biochem. (2015). doi: 10.1016/j.clinbiochem.2015.12.002 Google Scholar
  25. 25.
    A.I. Sebba, S.L. Bonnick, R. Kagan, D.E. Thompson, C.S. Skalky, E. Chen, A.E. de Papp, Fosamax Actonel Comparison Trial Investigators, Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr. Med. Res. Opin. 20(12), 2031–2041 (2004)CrossRefPubMedGoogle Scholar
  26. 26.
    K. Saag, R. Lindsay, A. Kriegman, E. Beamer, W. Zhou, A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 40(5), 1238–1243 (2007)CrossRefPubMedGoogle Scholar
  27. 27.
    D.L. Kendler, C. Roux, C.L. Benhamou, J.P. Brown, M. Lillestol, S. Siddhanti, H.S. Man, J. San Martin, H.G. Bone, Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J. Bone. Miner. Res. 25, 72–78 (2010)CrossRefPubMedGoogle Scholar
  28. 28.
    R. Eastell, J.H. Krege, P. Chen, E.V. Glass, J.Y. Reginster, Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr. Med. Res. Opin. 22, 61–66 (2006)CrossRefPubMedGoogle Scholar
  29. 29.
    M. Tsujimoto, P. Chen, A. Miyauchi, H. Sowa, J.H. Krege, PINP as an aid for monitoring patients treated with teriparatide. Bone 48, 798–803 (2009)CrossRefGoogle Scholar
  30. 30.
    D.C. Bauer, A. Schwartz, L. Palermo, J. Cauley, M. Hochberg, A. Santora, S.R. Cummings, D.M. Black, Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern. Med. 174(7), 1126–1134 (2014)CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    R.E. Marx, J.E. Cill Jr, J.J. Ulloa, Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J. Oral Maxillofac. Surg. 65(12), 2397–2410 (2007)CrossRefPubMedGoogle Scholar
  32. 32.
    S.L. Ruggiero, T.B. Dodson, J. Fantasia, R. Goodday, T. Aghaloo, B. Mehrotra, F. O’Ryan, American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update. J. Oral Maxillofac. Surg. 72(10), 1938–1956 (2014)CrossRefPubMedGoogle Scholar
  33. 33.
    A. Hutcheson, A. Cheng, R. Kunchar, B. Stein, P. Sambrook, A. Goss, A C-terminal crosslinking telopeptide test-based protocol for patients on oral bisphosphonates requiring extraction: a prospective single-center controlled study. J. Oral Maxillofac. Surg. 72(8), 1456–1462 (2014)CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Clinical Biochemistry, PathWest Laboratory Medicine WAFiona Stanley HospitalMurdochAustralia
  2. 2.School of Pathology and Laboratory MedicineUniversity of Western AustraliaNedlandsAustralia
  3. 3.School of Medicine and PharmacologyUniversity of Western AustraliaNedlandsAustralia

Personalised recommendations